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Background: Primary immunodeficiency diseases (PIDs) comprise a heterogeneous group of disorders mainly
characterized by increased susceptibility to infections. The aims of this study were to estimate the occurrence rate of
PID in the paediatric (age≤ 18 years) population of southern Sweden (approx. 265,000 children) and to describe their
demographic, clinical and immunological characteristics. During a period of 4 years, in four paediatric speciality clinics
in Skåne County in southern Sweden, children being seen for infections and fulfilling specific criteria were evaluated
according to a predefined examination schedule. The initial analysis consisted of complete blood counts with analysis
of lymphocyte subpopulations (T, B, NK cells), measurement of immunoglobulins (IgG, IgA, IgM, IgE and IgG
subclasses), and assessment of the complement system (classical, alternative and lectin pathways). In addition, results of
these immunological analyses in other children from the same area and time period were evaluated.
Results: In total, 259 children (53.6% males) met the criteria and were included. The most common infection was
recurrent otitis media. Immunological analyses results for about two thirds of the patients were outside age-related
reference intervals. Further examination in this latter group identified 15 children with PID (9 males); 7 (2.7%) had
genetically defined PID, representing 4 different diagnoses, and another 8 (3.1%) had a clinically defined PID - common
variable immunodeficiency. No additional PID patient was identified from the evaluation of laboratory results in
children not included in the study. The median age at diagnosis was 3.5 years (range 1–12 years).
Conclusions: The occurrence rate of PID was about 4 new cases per year in this population. Several different PID
diagnoses were found, and the application of specified criteria to identify PID patients was useful. In children who are
prone to infection, the use of a predefined set of immunological laboratory analyses at their first examination was
beneficial for early identification of patients with PID.
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Primary immunodeficiency diseases (PIDs) are a heteroge-
neous group of disorders mainly characterized by severe
and recurrent infections but also increased susceptibility
to autoimmune conditions and malignancies. PIDs are
relatively rare in the general population, affecting between
1 in 500 to 1 in 500,000 individuals, with varying degrees
of ascertainment in different countries [1-5]. Most PIDs
are hereditary, and many of these diseases present during
infancy or in early childhood [6]. Because recurrent or* Correspondence: Nicholas.Brodszki@skane.se
1Children’s Hospital, Skåne University Hospital, Lund SE-22185, Sweden
Full list of author information is available at the end of the article
© 2014 Brodszki et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.severe infections are important clinical characteristics of
PID, early detection of PID is critical, before these infec-
tions compromise a patient’s general condition. A correct
and early diagnosis is needed for optimal treatment and
for timely family genetic counselling [7].
Children suffer more often than adults from infections,
and infection frequency is higher in younger age groups.
This pattern is especially true for children who are regu-
larly exposed to infectious agents, such as those attending
institutional day care [8]. Because few children have a
demonstrable PID, it can be challenging for the investigat-
ing physician to identify in this group the relatively rare
child with an immunodeficiency. Based on estimations of
frequency of several forms of PID, a considerablel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Inclusion criteria for evaluation of primary
immunodeficiency disease*
1) Six or more new ear infections within 1 year; otitis with
complications such as chronic perforation or mastoiditis
2) Two or more serious sinus infections within 1 year
3) Infections that do not heal as expected during antibiotic
treatment
4) Two or more pneumonias within 1 year
5) Failure of an infant to gain weight or grow normally
6) Recurrent, deep skin infections or organ abscesses
7) Chronic severe oral or cutaneous candidiasis
8) Infections caused by unusual microbial agents and/or with
unusual localization
9) Two or more invasive infections such as osteomyelitis,
meningitis or sepsis
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nosis in a timely fashion [9,10]. From our own experience,
we believe that there are more children with PID than
published statistics would suggest [11].
The objectives of this study were to estimate the oc-
currence rate of PID in the paediatric population of
southern Sweden and to describe their demographic,
clinical and immunological characteristics. Children in a
defined area in southern Sweden who needed health care
for infections and fulfilling specific criteria were evalu-
ated according to a predefined examination schedule in-
cluding a set of laboratory analyses. In total, 15 children
with PID, representing five diagnoses, were identified
during a 4-year period in a paediatric population of
around 265,000 (ages ≤18 years).10) A family history of PID
11) Recurrent fever or fever lasting more than 6 weeks
12) Excessive number of upper respiratory tract infections
(more than 8 per year)
*The first 10 criteria are identical to the “10 Warning Signs” given by Swedish
Physicians Working with Immunodeficiency (SLIPI) [12].Methods
Patients
The study area consisted of Skåne, the southernmost
county in Sweden with a population of 1.2 million.
Region Skåne is a regional public body with adminis-
trative and financial responsibility for the health of
the inhabitants and for providing medical and dental
services. In Region Skåne, there are four major paedi-
atric clinics where children with suspected PID are
evaluated, and all diagnostic immunological analyses
are performed at one accredited laboratory (Clinical
Immunology and Transfusion Medicine, Laboratory
Medicine Skåne, Lund, Sweden).
The children in the study were referred to the four
clinics from either general practitioners or paediatricians,
and the main reason for referral was a history of recurrent
infections. During a period of 4 years, from October 2007
to November 2011, the children presenting for health care
for frequent infections at these four clinics were evaluated
according to a predefined examination schedule. The
paediatric population in Skåne (≤18 years), in the middle
of the study period (December 2009), was 268,439 (13.1%
of all children in Sweden).
The criteria for evaluation and thus inclusion in the
study were based primarily on the “10 Warning Signs”
(Table 1) defined by the Swedish Physicians Working
with Immunodeficiency (SLIPI) [12]. Because other clin-
ical symptoms can raise the suspicion of PID, we ex-
tended the inclusion criteria beyond the 10 warning
signs to incorporate the following additional symptoms:
recurrent fever or fever with duration of more than
6 weeks, and an excessive number of upper respiratory
tract infections (>8 per year) [8]. The examination
schedule consisted of medical history, physical examin-
ation and a predefined set of laboratory analyses. Blood
samples were stored to permit later analysis of disease
genes, specific antibodies and other immune molecules.Ethical permission for the study was obtained from the
Regional Ethical Review Board, Lund, Sweden (LU 300/
2007). Written informed consent for participation in the
project and for storage of the blood samples for later
analysis was obtained from all patients and their custo-
dians. Permission for storage of DNA data was obtained
from the local division of The Swedish Data Inspection
Board.
To ensure that no children with symptoms suggestive
of PID were missed, the results of the same immuno-
logical laboratory analysis as included in the predefined
set, performed in other children (ages 0–18 years) from
the same area, during the same time period, were also
analysed. This additional evaluation was possible be-
cause all of these analyses were performed at the same
Lund laboratory.
Laboratory analysis
Complete blood counts were measured using standard la-
boratory methods. Analysis of lymphocyte subpopulations
defined by expression of CD3 (T cells), CD4 (T helper
cells), CD8 (T cytotoxic cells), CD19 (B cells) and CD16/
56 (NK cells) was performed by flow cytometry. Serum
immunoglobulin (Ig) concentrations including IgG, IgA,
IgM, IgE and IgG subclasses were measured using nephe-
lometry. The functions of classical, alternative and lectin
pathways of complement in serum were assessed with the
Wieslab® Complement system Screen kit (Euro Diagnos-
tica, Malmö, Sweden) [13] and concentrations of the
components C3 and C4 by nephelometry, while C1q
and properdin levels were determined with electroim-
munoassay and mannose-binding lectin (MBL) level
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plement components was performed in patients with
abnormal results in the functional complement assays.
Because all immunological analyses in southern Sweden
are performed at our laboratory, we have access to the re-
sults for all children tested during the study period in this
area. The immunological tests are offered by default as
certain combinations (clusters) at our laboratory and are
recommended for investigating patients with infection
proneness, thus allowing the possibility of comparing the
results of any patient with the study patients. The tests
performed for patients examined outside the study were
either only one or a combination of the following clusters:
Ig, Ig subclasses, complement and lymphocyte subpopula-
tions. Results from these immunological analyses in chil-
dren from departments where they were investigated for
reasons other than suspicion of PID (e.g. oncology, trans-
plantation, rheumatology and nephrology) were excluded.
Results
Demographic characteristics
During a 4-year period, from October 2007 to November
2011, a total of 327 patients were evaluated in accord-
ance with our predefined schedule (Figure 1). Of these
patients, 41 did not meet any of the inclusion criteria.
Nevertheless, the clinicians responsible for these patients
considered that an immunologic assessment should beFigure 1 Flow chart and summarized results for patients included in
did not meet the inclusion criteria or they had a known disease predisposing
with immunological laboratory results within (Normal) or outside the referenc
(Co) are given. The number of patients and type of PID found in those with d
Methods section; AAg, autosomal agammaglobulinaemia; C2D, complement
syndrome; PF, periodic fever, aphthous stomatitis, pharyngitis and adenitis; XLdone and used our schedule to start the evaluation. An-
other 27 patients were also excluded from the final ana-
lysis because of an already known underlying chronic or
genetic disease (e.g. 22q11 deletion syndrome or cystic
fibrosis) that predisposes to infections.
The age interval of the 259 children included was from
1 month to 17 years with a median age of 28 months.
There were 139 (53.6%) males and 120 females (46.4%)
(Figure 2). The majority (n = 240) were Caucasians of
European descent; 17 patients were of Middle-Eastern
origin and two were of Asian origin.
According to the medical records, the study patients
were characterized by recurrent, but not always severe,
infections. In total, 52 patients fulfilled more than one
criterion, 43 had two criteria, 6 had three criteria and 3
had four criteria fulfilled. The most common reason for
investigation was recurrent otitis media (n = 102 pa-
tients). As expected, a clear relationship with age was
seen for the ear infections, with the majority of these pa-
tients just over age 2 years (median 25 months, range
6 months to 9 years). The second most common infec-
tion type was pneumonia (n = 52) followed by abnormal
number of upper respiratory tract infections (n = 35).
During the same 4-year period, another 2442 unique
patients with infection proneness were analysed with
one or two of the laboratory clusters described in the
Methods. Only 19 patients were analysed with the samethe study. Of 327 patients enrolled, 68 were excluded because they
for infections. For the remaining 259 patients, the number of patients
e intervals for immunoglobulins (Ig), lymphocytes (Ly) and complement
eviating results are also shown. The analyses performed are stated in the
C2 deficiency; CVID, common variable immunodeficiency; HIES, hyper-IgE
A, X-linked agammaglobulinaemia.
Figure 2 Age distribution of the patients. A. Age distribution of the included 259 study patients (120 female and 139 males). B. Age distribution of
patients with a PID diagnosis. Abbreviations of diagnoses as in Figure 1.
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normal results.
Immunological laboratory findings
Only about one third of the 259 patients (35.5%) had re-
sults of the immunological analyses within the age-
matched reference intervals. Many of the study patients
with abnormal laboratory results had several abnormal
findings (Figure 1). Seven patients (2.7%) had a genetic-
ally identified and another eight patients a clinically de-
fined PID. As seen in Figure 1, all patients who received
a PID diagnosis had abnormal laboratory results. The re-
sults of the immunological analyses in the study patients
and in other children with infections from county ofSkåne are presented in Table 2. None of the patients
outside the study received a PID diagnosis.Immunoglobulin
As expected, considering the median age of the children,
the most common finding regarding results of Ig analysis
was IgG subclass deficiency, defined as significantly de-
creased concentration of one or more subclasses of IgG
in a patient with normal IgG concentration [14]. The
distribution of the different deficiencies among the 32
patients and their treatment are given in Table 3. No pa-
tients had selective IgA deficiency, defined as a serum
IgA level <0.07 g/L and age over 4 years.
Table 2 Children with suspected primary immunodeficiency disease with results of immunological analysis outside
reference intervals
Study (n = 259)a No. (%) Excluded (n = 41)b No. (%) Skånec county No. (%)
Immunoglobulins IgG 21 (8.1) 0 16 (1.5)
IgA 0 0 1 (0.1) n = 1056
IgM 21 (8.1) 0 37 (3.5)
Immunoglobulin subclasses IgG1 0 0 10 (1.0) n = 1080
IgG2 24 (9.2) 0 59 (5.4)
IgG3 4 (1.4) 0 0
IgG1 + IgG2 1 (0.4) 0 3 (0.3)
IgG1 + IgG3 0 0 3 (0.3)
IgG2 + IgG3 1 (0.4) 0 1 (0.1)
Lymphocytes T cells 34 (13.1) 5 (12.2) 17 (4.8) n = 348
T helper cells 2 (0.7) 0 1 (0.3)
T cytotoxic cells 4 (1.4) 2 (4.8) 0
B cells 19 (7.3) 1 (2.4) 4 (1.1)
NK cells 13 (5.0) 0 13 (3.7)
Complement Classical pathway 9 (3.5) 1 (2.4) 26 (1.7) n = 1473
Alternative pathway 5 (1.9) 0 14 (0.9)
Lectin pathway 63 (24.3) 4 (9.6) 26 (18.4) n = 141
aPatients fulfilling the study inclusion criteria.
bThe 41 patients not fulfilling the study inclusion criteria but with results from the predefined set of immunological analyses (the 27 patients excluded because of
known genetic diseases are omitted).
cOther patients with infections in which immunological analyses were performed.
Table 3 Patients with IgG subclass deficiency
Deficiencya No. of patients Treatment
IgG1 0 -
IgG2 23 Ig infusion: 5 patients
IgG3 4 -
IgG4b 0 -
IgG1 + IgG2 1 Ig infusion
IgG1 + IgG3 0 -
IgG2+ IgG3 1 Ig infusion
IgG2 + IgA 3 Ig infusion: 1 patient
IgG3 + low IgA, IgM 1 Ig infusion
aDefined as a significant decrease in serum concentration of one or more
subclasses of IgG when total IgG concentration is normal (6). Values below
age-matched reference intervals were considered as significantly decreased.
bAge >12 years.
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The measurement of complete blood counts did not lead
to identification of any additional PID cases that were
not also found by the immunological analyses. More
than one in four of the patients (27.4%) had an abnormal
result in the lymphocyte analyses (Figure 1). Many of
these patients had, for their age, a higher than expected
number of viral upper respiratory tract infections as
their only clinical characteristic. Analysis of the lympho-
cyte subpopulations revealed no patients with total
deficiency of T cells, but relative to the age-matched ref-
erence interval, there were 34 patients with low levels.
In total, 24 patients (63% males) had low numbers of
circulating B cells, some of them in combination with
variably low numbers of T cells. All of these patients had
normal levels of the Ig isotypes measured. The numbers
of patients with isolated aberrancies in any of the
lymphocyte subpopulations are shown in Figure 3.
Complement
About one fifth of the patients (20.5%) did not have all
results of the complement analyses within the reference
intervals (Figure 1). Nine patients had decreased func-
tion of the classical pathway without a common clinical
denominator. Five patients showed decreased function
of the alternative pathway. Two of these could be ex-
plained by low levels of properdin, but three of themwere unexplained, and there was no common clinical as-
sociation. Nineteen patients had low levels of C1q with-
out any detectable C1q antibodies. Of these, seven are
currently on Ig infusions. Although they received Ig for
reasons other than the low C1q (two because of X-
linked agammaglobulinaemia [XLA], four because of
common variable immunodeficiency [CVID] and one for
IgG2 deficiency), this finding confirms the described
direct association of low C1q levels with low IgG levels
[15], that C1q concentration is age-dependent and that
Figure 3 Results of the lymphocyte analysis. Number of patients with an isolated subnormal number of T, B and NK cells shown together
with the number of patients with an isolated low number of T cell subpopulations. In total, 72 of 259 patients had lymphocyte analysis results
below reference intervals.
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perdin were found in 15 patients.
MBL deficiency, defined as MBL concentration <100 μg/L,
was a common finding, identified in 63 cases (24.3%).
The high incidence of MBL deficiency is not explained
by the age of patients [17] or ancestry because the ma-
jority of the patients were of Scandinavian ancestry,
and the supposed frequency in this group is approxi-
mately 10% [18]. The main reason for investigation of
these children was otitis media, thus confirming earlier
observations that the lectin pathway plays a role in
upper airway infections during early childhood [19].
The importance of MBL deficiency alone is question-
able, and we do not here refer to the patients with this
laboratory test result as having an immunodeficiency.
Clinical outcome
The patients with laboratory results or clinical symp-
toms that indicated a PID disease have been followed for
a period of between 2 to 6 years. We have identified PID
in 15 children (Figure 2B), seven with genetically defined
PID disease and eight with a clinically defined PID diag-
nosis [1].
Genetically defined PID
Three patients were diagnosed with XLA with defects in
the Bruton tyrosine kinase gene. One patient with IgG2
deficiency and a defect in the complement classical
pathway was diagnosed with complete C2 deficiency
type 1. One patient with high IgE serum concentration
was confirmed to have a mutation in the STAT3 gene,
leading to the diagnosis of Hyper-IgE syndrome. Finally,
two female patients with no B cells had mutations in theIGLL1 gene, and their diagnosis was autosomal recessive
agammaglobulinaemia. During the study period, no pa-
tients with severe combined immunodeficiency (SCID)
were identified in the county of Skåne.
Clinically defined PID
In this cohort, several patients had well-characterized
PID but without a known genetic defect. Thus, we diag-
nosed eight patients with CVID, defined as a patient
older than age 2 years with IgG and IgA and/or IgM
levels two standard deviations below the mean for age
and an absence of other detectable immunodeficiency
[20,21]. Nine of the patients could be classified as having
transient hypogammaglobulinaemia of infancy or unclas-
sified hypogammaglobulinaemia as recently defined by
the European Society for Immunodeficiency (ESID) [22].
However, we do not here specify these as patients with
PID because the study design did not allow us to distin-
guish between these two groups and the significance of
this deficiency is questionable.
Other diagnosis than PID
During the follow-up, seven of the tested patients fulfilled
the criteria for one of the known autoinflammatory syn-
dromes [23], for a diagnosis of periodic fever, aphthous
stomatitis, pharyngitis and adenitis (known as PFAPA).
None of these patients showed any immunological aberra-
tions, emphasizing the importance of evaluating patient
symptoms.
Discussion
Early diagnosis and adequate therapy are the keys to sur-
vival and a better quality of life for patients with PID. To
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cused on the infection proneness typical for PID and
used specified inclusion criteria. Similar warning signs
have been implemented by ESID after initiation of the
present investigation [22]. Comparable warning signs are
used worldwide and have been suggested by the Jeffrey
Modell Foundation [24], the United States Immunodefi-
ciency Network and the Immune Deficiency Foundation
[25]. However, the warning signs carry limitations as a
screening tool because they may fail to identify some pa-
tients with serious PIDs, as recently reported [26,27].
The warning sign of having a family member with a
known immunodeficiency is advocated as one of the
three most important signs for identifying patients with
PID [27]. In our study, however, only four children met
this criterion, most likely because the ethnic background
of our population suggests a very low percentage of con-
sanguinity. However, one patient with a genetic deficiency
was discovered through this warning sign, indicating its
importance. In our study, recurrent otitis media was the
most common type of infection prompting the study pa-
tients to seek health care, which is explained by the age
distribution characteristic for this diagnosis [28].
The children included were all investigated with a pre-
defined standardized “starting kit” of immunological ana-
lyses that are generally available and easy to perform. We
believe this approach would help physicians with the ini-
tial evaluation of patients suspected of having PID and
thus lead to an early diagnosis; indeed, all PID patients we
found had laboratory results outside reference intervals.
However, because these analyses also were performed in
other children not included in the study, we used available
laboratory data to ensure that no PID patients were
missed. A certain number of results in these other chil-
dren were not within the normal reference ranges, but be-
cause no additional patient with PID was found, this
outcome clearly suggests that all PID children in the area
were identified. Also, none of the test results led to the re-
ferral of any patient to any of the four paediatric clinics.
The information regarding PID occurrence in Sweden
is scarce. In a previous study based on a survey of symp-
tomatic PID in children in Sweden during a 6-year
period in the 1970s, 174 cases were found [29]. Consid-
ering the population in Sweden of about 9.5 million, our
number of 15 cases during 4 years in a population of 1.2
million is of the same magnitude. In our cohort, a rela-
tively low predominance of boys was seen, with a male/
female ratio of 1.1/1, compared to previously described
cohorts in which this ratio was 1.4/1 to 2/1 [29,30]. A
possible explanation for our results is the different re-
cruitment method because we included all patients with
symptoms suggestive of PID who sought health care.
Regarding the 32 patients with IgG subclass deficien-
cies, our findings are similar to earlier observations [31].The significance of IgG subclass deficiency in childhood
is controversial, and we thus did not include these pa-
tients in the number of PID patients. However, as seen
in Table 3, these patients still need treatment, and
checking for this deficiency should be done. The absence
of selective IgA deficiency was noted but is reasonably
explained by the low number of patients older than
4 years. We chose not to include the results from ana-
lysis of specific antibodies in this report because the
Swedish official immunization schedule for children was
changed during the study, making interpretation com-
plex, but the aim is to include these findings in a forth-
coming publication.
Considering the results of the lymphocyte analyses, a
fair proportion of the patients showed a subnormal con-
centration of one or several lymphocyte subpopulations.
Clearly, the number of such patients found in our study
is higher than expected, but the results could not be as-
sociated with any particular diagnosis or symptoms.
Changes in distribution of lymphocyte subpopulations
occur often in infections. The deviations noted could be
temporary, but the design of the study did not make this
possible to verify. The justification of the lymphocyte
analysis, however, is the need to detect severe PIDs like
SCID and XLA without delay. Further studies are war-
ranted to define the role for these analyses of the im-
mune system in this patient group.
A few children showed reduced activity in the func-
tional test for the alternative complement pathway with-
out any known cause. This outcome is in line with
previous observations that defective function in this
pathway occasionally is seen in sera from newborns [32].
An interesting finding was the great number of patients
with a non-functioning lectin pathway. Eleven (17%) of
the patients with MBL deficiency were given treatment
(antibiotic prophylaxis). Of these, 4 patients had no
other immunological analysis with discrepant result, sug-
gesting that MBL deficiency may be the sole reason for
their recurrent infections. Considering the percentage of
patients in need of treatment, these findings are highly
relevant for the practicing clinician. There is also con-
vincing evidence in the literature that MBL deficiency is
associated with increased morbidity risk when immunity
is co-compromised by another defect [33], as in cystic fi-
brosis [34], although the nature of the association may
vary [18]. Another example is that the combination of
C2 deficiency and MBL deficiency appears to increase
infection proneness [35]. Thus, MBL deficiency may be
regarded as a disease modifier, but some patients with
this deficiency and no other known defect in their im-
mune system still require treatment.
We argue therefore that testing the function of the
complement system should be done early during an im-
munological evaluation. The defects in the complement
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complications are avoidable if the defect is identified
early enough. In C2 deficiency, vaccination against the
encapsulated bacteria S. pneumoniae and H. influenzae
can give rise to antibodies and opsonisation, clearly sug-
gesting increased protection [36]. Vaccination against
other encapsulated bacteria such as meningococci is also
recommended in complement deficiency states.
We identified eight patients with CVID, which is fewer
than expected from previously published studies [37].
CVID is usually diagnosed in the second or third decade
of life, but conform to a recent study 33.7% of CVID pa-
tients present before the age of 10 years [38], and there
is a described earlier peak of diagnosis at approximately
age 8 years [39]. The diagnosis of CVID before age
6 years is questionable because of a possible delay in im-
munologic maturation and because transient hypogamma-
globulinaemia of infancy may persist in some children
[40]. We think that our low numbers are the result of the
fact that the mean age in this cohort of patients was low
and the follow-up time for many of them was not long
enough.
The fact that no patients with SCID were identified in
southern Sweden during this period is in concordance
with the published statistics considering the frequency of
SCID [6] because the number of children born every
year in Skåne is approximately 12,500.
A limitation of our study is that because there are
PIDs with a non-infectious phenotype, they might have
been missed given that the warning signs do not contain
that type of symptom [26,27]. Another weakness is that
from our data, it is impossible to estimate the prevalence
of PID in the county of Skåne. The study period was only
4 years; the age of onset of many PIDs is very broad, how-
ever, and some patients might not yet have presented with
symptoms. Many of the patients included underwent la-
boratory analysis only once, so that an abnormal value
might be normal if the analysis were repeated; the con-
trary might be true for a normal value, as well. Some ab-
normal values are likely explained by an ongoing infection
and not an underlying PID. However, this is the situation
when the sick child is seen by the physician, and our re-
sults clearly show the usefulness of the standardized start-
ing set of immunological laboratory tests in combination
with the clinical warning signs. Saving blood samples, in-
cluding cells, for DNA analysis makes it possible to add
genetic analysis without a repeated sampling. Also, there
may be an opportunity of diagnosing an immunodefi-
ciency disease that has yet to be identified but might be
characterized in the near future.
In 2012, after the start of our study, an updated ver-
sion of a diagnostic protocol for screening for PID was
published by the ESID Clinical Working Party [41]. We
are aware that the multi-stage protocol differs to someextent from ours. However, we consider that our results
are relevant because our protocol allows patient identifi-
cation early in the diagnostic process.
Conclusions
The use of specified criteria in children presenting for
health care for infections and evaluation according to a
predefined examination schedule, including a set of la-
boratory analyses, is useful for identifying children with
PID. In the studied paediatric population of around
265,000 (ages ≤18 years) in southern Sweden, about four
new cases of PID per year were seen provided that un-
classified hypogammaglobulinaemia and MBL deficiency
were not included as PID diagnoses.
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